Journalartikel

Jahr der Veröffentlichung: 2024

Seiten: 579-590

Zeitschrift: Patient Preference and Adherence

Bandnummer: 18

ISSN: 1177-889X

Open Access Status: Gold

DOI Link: https://doi.org/10.2147/PPA.S440818

Verlag: Taylor and Francis Group

Abstract: 
Purpose: Prefilled syringes (PFS) and various types of pens are available for subcutaneous injection of methotrexate (MTX) in patients with rheumatoid arthritis or moderate to severe psoriasis. A new MTX pen with modernized button -free autoinjection technology was developed as a successor to a button -activated pen (metoject (R)/metex (R) PEN). To assess the needs of users and the relevance of features of the new MTX autoinjector an international online survey was performed. Methods: A structured questionnaire was distributed to physicians, nurses and patients in Germany, France, and the United Kingdom. Participants received illustrations and information about features of the new MTX autoinjector. Results: In total, 189 rheumatologists, 111 dermatologists, 90 nurses, and 180 patients answered the questions. Specific reasons for a preference for the use of MTX pens over PFS could predominantly be assigned to the categories "dosing/administration" and "ease of use". The first impression of the new MTX autoinjector was positive in 82% of physicians, 87% of nurses, and 76% of patients, respectively. The four most important features of the new MTX autoinjector were 2 -step autoinjector mechanism (receiving a mean 14.1 to 18.1 chips of a total of 100 chips), small injection volume (9.7 to 11.7 chips), 10 different doses for dose flexibility (8.0 to 13.2 chips), and short injection time below 5 seconds (8.5 to 11.1 chips). Conclusion: Arguments for the use of MTX pens as opposed to PFS predominantly refer to dosing/administration and ease of use. The new button -free MTX autoinjector combines a number of advantageous features identified by the international survey.

Harvard-Zitierstil: Mueller-Ladner, U., Edwards, C. and Erkens, A. (2024) International Survey to Evaluate Current Options for Subcutaneous Injection of Methotrexate (MTX) and a New Button-Free MTX Autoinjector, Patient Preference and Adherence, 18, pp. 579-590. https://doi.org/10.2147/PPA.S440818

APA-Zitierstil: Mueller-Ladner, U., Edwards, C., & Erkens, A. (2024). International Survey to Evaluate Current Options for Subcutaneous Injection of Methotrexate (MTX) and a New Button-Free MTX Autoinjector. Patient Preference and Adherence. 18, 579-590. https://doi.org/10.2147/PPA.S440818